VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.) Announces Issuance of Two Key U.S. Patents Covering DNA Plasmid Manufacturing Technology and the Treatment of Anemia

BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals today announced that it has been granted U.S. Patent number 7,238,522 covering its DNA plasmid manufacturing technology. The patent entitled, “Device and Methods for Biomaterial Production” represents the first to issue of a series of applications related to VGX’s novel approach to DNA plasmid manufacturing.

MORE ON THIS TOPIC